Advances in immune-based therapies of renal cell carcinoma

Expert Review of Anticancer Therapy

Volumn 4, Issue 6, 2004, Pages 1081-1096

  Lam, John S ^a   Belldegrun, Arie S ^a   Figlin, Robert A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Carbonic anhydrase; Cytokines; Dendritic cells; Immunotherapy; Lymphocytes; Renal cell carcinoma; Tumor associated antigen; Vaccines

Indexed keywords

ALPHA2B INTERFERON; BCG VACCINE; BETA INTERFERON; BEVACIZUMAB; CARBONATE DEHYDRATASE; CYCLOOXYGENASE 2 INHIBITOR; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; FLUOROURACIL; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HLA B7 ANTIGEN; HSPPC 96; INTERLEUKIN 12; INTERLEUKIN 4; IPILIMUMAB; ISOTRETINOIN; MEDROXYPROGESTERONE ACETATE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY G250; PANITUMUMAB; PEGINTERFERON; RECOMBINANT ALPHA INTERFERON; RECOMBINANT INTERLEUKIN 2; RECOMBINANT INTERLEUKIN 4; RETINOIC ACID; TAMOXIFEN; THALIDOMIDE; TRANSFORMING GROWTH FACTOR BETA ANTIBODY; TUMOR VACCINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; VINBLASTINE;

ADOPTIVE TRANSFER; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIGEN PRESENTING CELL; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG POTENTIATION; DRUG RESPONSE; HUMAN; HYPOTENSION; KIDNEY CARCINOMA; KIDNEY DISEASE; LUNG EDEMA; METASTASIS; MONOTHERAPY; NEPHRECTOMY; NEUROPATHY; NEUROTOXICITY; REVIEW; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; T LYMPHOCYTE ACTIVATION;

EID: 10644258823     PISSN: 14737140     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737140.4.6.1081     Document Type: Review

References (135)

1. Jemal A, Tiwari RC, Murray T et al. Cancer statistics, 2004. CA Cancer J. Clin. 54, 8-29 (2004).
2. Janzen NK, Kim HL, Figlin RA, Belldegrun AS. Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol. Clin. North Am. 30, 843-852 (2003).
3. Pantuck AJ, Zisman A, Belldegrun AS. The changing natural history of renal cell carcinoma. J. Urol. 166, 1611-1623 (2001).
4. Pantuck AJ, Belldegrun AS, Figlin RA. Nephrectomy and interleukin-2 for metastatic renal-cell carcinoma. N. Engl. J. Med. 345, 1711-1712 (2001).
5. 2b alone for metastatic renal-cell cancer. N. Engl. J. Med. 345, 1655-1659 (2001).
6. Mickisch GH, Garin A, van Poppel H, de Prijck L, Sylvester R. Radical nephrectomy plus interferon-α-based immunotherapy compared with interferon-α alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 358, 966-970 (2001).
7. Figlin RA. Renal cell carcinoma: management of advanced disease. J. Urol. 161, 381-387 (1999).
8. Bukowski RM. Natural history and therapy of metastatic renal cell carcinoma: the role of interleukin-2. Cancer 80, 1198-1220 (1997).
9. Motzer RJ, Russo P. Systemic therapy for renal cell carcinoma. J. Urol. 163, 408-417 (2000).
10. Flanigan RC, Campbell SC, Clark JI, Picken MM. Metastatic renal cell carcinoma. Curr. Treat. Options Oncol. 4, 385-390 (2003).
11. Yagoda A, Abi-Rached B, Petrylak D. Chemotherapy for advanced renal-cell carcinoma: 1983-1993. Semin. Oncol. 22, 42-60 (1995).
12. Yu DS, Chang SY, Ma CP. The expression of mdr-1-related gp-170 and its correlation with anthracycline resistance in renal cell carcinoma cell lines and multi-drug resistant sublines. Br. J. Urol. 82, 544-547 (1998).
13. Marcus SG, Choyke PL, Reiter R et al. Regression of metastatic renal cell carcinoma after cytoreductive nephrectomy. J. Urol. 150, 463-466 (1993).
14. Nelson BH. IL-2, regulatory T-cells, and tolerance. J. lmmunol. 172, 3983-3988 (2004).
15. Blattman JN, Greenberg PD. Cancer immunotherapy: a treatment for the masses. Science 305, 200-205 (2004).
16. Fyfe G, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louie AC. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J. Clin. Oncol. 13, 688-696 (1995).
17. Gitlitz BJ, Figlin RA. Cytokine-based therapy for metastatic renal cell cancer. Urol. Clin. North Am. 30, 589-600 (2003).
18. Yang JC, Sherry RM, Steinberg SM et al. Randomized study of high-dose and low-dose interieukin-2 in patients with metastatic renal cancer. J. Clin. Oncol. 21, 3127-3132 (2003).
19. Jonasch E, Haluska FG. Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities. Oncologist 6, 34-55 (2001).
20. deKernion JB, Sarna G, Figlin R, Lindner A, Smith RB. The treatment of renal cell carcinoma with human leukocyte α -interferon. J. Urol. 130, 1063-1066 (1983).
21. Medical Research Council Renal Cancer Collaborators. Interferon-α and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Lancet 353, 14-17 (1999 ).
22. 2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J. Clin. Oncol. 17, 2859-2867 (1999).
23. Kankuri M, Pelliniemi TT, Pyrhonen S, Nikkanen V, Helenius H, Salminen E. Feasibility of prolonged use of interferon-α in metastatic kidney carcinoma: a Phase II study. Cancer 92, 761-767 (2001).
24. Nanus DM, Geng Y, Shen R, Lai HK, Pfeffer SR, Pfeffer LM. Interaction of retinoic acid and interferon in renal cancer cell lines. J. Interferon Cytokine Res. 20, 787-794 (2000).
25. 2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma. J. Clin. Oncol. 18, 2972-2980 (2000).
26. 2a with or without 13-cis retinoic acid in patients with progressive, measurable metastatic renal cell carcinoma. Cancer 101, 533-540 (2004).
27. 2a treatment in metastatic renal cell carcinoma. J. Clin. Oncol. 20, 1429-1430 (2002).
28. Clark PE, Hall MC, Miller A et al. Phase II trial of combination interferon-α and thalidomide as first-fine therapy in metastatic renal cell carcinoma. Urology 63, 1061-1065 (2004).
29. 2b three times daily and thalidomide in the treatment of metastatic renal cell carcinoma. J. Clin. Oncol. 21, 3770-3776 (2003).
30. 2b (IFN) + thalidomide (T) in patients (pts with previously untreated renal cell carcinoma (RCC). Improvement in progression-free survival (PFS) but not quality of life (QoL) or overall survival (OS). A Phase III study of the Eastern Co-operative Oncology Group (E2898). Proc. Am. Soc. Clin. Oncol. 23, 384 (2004) (Abstract 4516).
31. 2b treatment for patients with solid tumors: a Phase I/lI study. J. Clin. Oncol. 20, 3841-3849 (2002).
32. 2b and liposome-encapsulated all-trans retinoic acid in the treatment of patients with advanced renal cell carcinoma. Cancer 95, 1220-1227 (2002).
33. 2a: an active out-patient regimen in metastatic renal cell carcinoma. J. Clin. Oncol. 10, 414-421 (1992).
34. 2a in patients with advanced renal cell carcinoma. J. Clin. Oncol. 10, 1124-1130 (1992).
35. Atzpodien J, Lopez Hanninen E, Kirchner H et al. Multi institutional home-therapy trial of recombinant human interleukin-2 and interferon-α-2 in progressive metastatic renal cell carcinoma. J. Clin. Oncol. 13, 497-501 (1995).
36. 2a, or both in metastatic renal-cell carcinoma. Groupe Francais d'Immunotherapie. N. Engl. J. Med. 338, 1272-1278 (1998).
37. Atzpodien J, Kirchner H, Hanninen EL, Deckert M, Fenner M, Poliwoda H. Interleukin-2 in combination with interferon-α and 5-fluorouracil for metastatic renal cell cancer. Eur. J. Cancer 29A(Suppl. 5), S6-S8 (1993).
38. 2a-based immunochemotherapy in advanced renal cell carcinoma: a Prospectively Randomized Trial of the German Co-operative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). J. Clin. Oncol. 22, 1188-1194 (2004).
39. Negrier S, Caty A, Lesimple T et al. Treatment of patients with metastatic renal carcinoma with a combination of subcutaneous interleukin-2 and interferon-α with or without fluorouracil. Groupe Francais d'Immunotherapie, Federation Nationale des Centres de Lutte Contre le Cancer. J. Clin. Oncol. 18, 4009-4015 (2000).
40. Dutcher JP, Logan T, Gordon M et al. Phase II trial of interleukin-2, interferon-α, and 5-fluorouracil in metastatic renal cell cancer: a cytokine working group study. Clin. Cancer Res. 6, 3442-3450 (2000).
41. Dutcher J, Atkins MB, Margolin K et al. Kidney cancer: the Cytokine Working Group experience (1986-2001): part II Management of IL-2 toxicity and studies with other cytokines. Med. Oncol. 18, 209-219 (2001).
42. Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin-4 and downregulated by tumor necrosis factor-α. J. Exp. Med. 179, 1109-1118 (1994).
43. 2b: Phase I trial of patients with metastatic renal cell carcinoma or malignant melanoma. J. Clin. Oncol. 22, 2891-2900 (2004).
44. Hoffman DM, Figlin RA. Intratumoral interleukin-2 for renal-cell carcinoma by direct gene transfer of a plasmid DNA/DMRIE/DOPE lipid complex. World J. Urol. 18, 152-156 (2000).
45. Chambers CA, Kuhns MS, Egen JG, Allison JP. CTLA-4-mediated inhibition in regulation of T-cell responses: mechanisms and manipulation in tumor immunotherapy. Ann. Rev. Immunol. 19, 565-594 (2001).
46. Phan GQ, Yang JC, Sherry RM et al. Cancer regression and autoimmunity induced by cytotoxic T-lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc. Natl Acad. Sci. USA 100, 8372-8377 (2003).
47. Pruthi RS, Derksen E, Gaston K. Cyclooxygenase-2 as a potential target in the prevention and treatment of genitourinary tumors: a review. J. Urol. 169, 2352-2359 (2003).
48. Gorelik L, Flavell RA. Immune-mediated eradication of tumors through the blockade of transforming growth factor-β signaling in T-cells. Nature Med. 7, 1118-1122 (2001).
49. Kausch I, Bohle A. Antisense oligonucleotide therapy in urology. J. Urol. 168, 239-247 (2002).
50. Hoffman DM, Gitlitz BJ, Belldegrun A, Figlin RA. Adoptive cellular therapy. Semin. Oncol. 27, 221-233 (2000).
51. Rosenberg SA. Karnofsky Memorial Lecture. The immunotherapy and gene therapy of cancer. J. Clin. Oncol. 10, 180-199 (1992).
52. Law TM, Motzer RJ, Mazumdar M et al. Phase III randomized trial of interleukin-2 with or without lymphokine-activated killer cells in the treatment of patients with advanced renal cell carcinoma. Cancer 76, 824-832 (1995).
53. Rosenberg SA, Lotze MT, Yang JC et al. Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. J. Natl Cancer Inst. 85, 622-632 (1993).
54. Koo AS, Tso CL, Shimabukuro T, Peyret C, deKernion JB, Belldegrun A. Autologous tumor-specific cytotoxicity of tumor-infiltrating lymphocytes derived from human renal cell carcinoma. J. Immunother. 10, 347-354 (1991).
55. Finke JH, Rayman P, Hart L et al. Characterization of tumor-infiltrating lymphocyte subsets from human renal cell carcinoma: specific reactivity defined by cytotoxicity, interferon-gamma secretion, and proliferation. J. Immunother. Emphasis Tumor Immunol. 15, 91-104 (1994).
56. Figlin RA, Pierce WC, Kaboo R et al. Treatment of metastatic renal cell carcinoma with nephrectomy, interleukin-2 and cytokine-primed or CD8(+) selected tumor infiltrating lymphocytes from primary tumor. J. Urol. 158, 740-745 (1997).
57. Bukowski RM, Sharfman W, Murthy S et al. Clinical results and characterization of tumor-infiltrating lymphocytes with or without recombinant interleukin-2 in human metastatic renal cell carcinoma. Cancer Res. 51, 4199-4205 (1991).
58. Figlin RA, Thompson JA, Bukowski RM et al. Multicenter, randomized, Phase III trial of CD8(+) tumor-infiltrating lymphocytes in combination with recombinant interleukin-2 in metastatic renal cell carcinoma. J. Clin. Oncol. 17, 2521-2529 (1999).
59. Yoshizawa H, Chang AE, Shu S. Specific adoptive immunotherapy mediated by tumor-draining lymph node cells sequentially activated with antiCD3 and IL-2. J. Immunol. 147, 729-737 (1991).
60. Chang AE, Aruga A, Cameron MJ et al. Adoptive immunotherapy with vaccine-primed lymph node cells secondarily activated with antiCD3 and interleukin-2. J. Clin. Oncol. 15, 796-807 (1997 ).
61. Chang AE, Li Q, Jiang G, Sayre DM, Braun TM, Redman BG. Phase II trial of autologous tumor vaccination, antiCD3-activated vaccine-primed lymphocytes, and interleukin-2 in stage IV renal cell cancer. J. Clin. Oncol. 21, 884-890 (2003).
62. Craddock C. Haemopoietic stem-cell transplantation: recent progress and future promise. Lancet Oncol. 1, 227-234 (2000).
63. Childs R, Chernoff A, Contentin N et al. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N. Engl. J. Med. 343, 750-758 (2000).
64. Rini BI, Zimmerman T, Stadler WM, Gajewski TF, Vogelzang NJ. Allogeneic stem-cell transplantation of renal cell cancer after nonmyeloablative chemotherapy: feasibility, engraftment, and clinical results. J. Clin. Oncol. 20, 2017-2024 (2002).
65. Derweesh IH, Tannenbaum CS, Rayman PA, Finke JH. Mechanisms of immune dysfunction in renal cell carcinoma. Cancer Treat. Res. 116, 29-51 (2003).
66. Uzzo RG, Clark PE, Rayman P et al. Alterations in NF-κB activation in T-lymphocytes of patients with renal cell carcinoma. J. Natl Cancer Inst. 91, 718-721 (1999).
67. Uzzo RG, Rayman P, Kolenko V et al. Mechanisms of apoptosis in T-cells from patients with renal cell carcinoma. Clin. Cancer Res. 5, 1219-1229 (1999).
68. Uzzo RG, Rayman P, Kolenko V et al. Renal cell carcinoma-derived gangliosides suppress nuclear factor-κB activation in T-cells. J. Clin. Invest. 104, 769-776 (1999).
69. Gaugler B, Brouwenstijn N, Vantomme V et al. A new gene coding for an antigen recognized by autologous cytolytic T-lymphocytes on a human renal carcinoma. Immunogenetics 44, 323-330 (1996).
70. Brandle D, Brasseur F, Weynants P, Boon T, Van den Eynde B. A mutated HLA-A2 molecule recognized by autologous cytotoxic T-lymphocytes on a human renal cell carcinoma. J. Exp. Med. 183, 2501-2508 (1996).
71. Schendel DJ, Gansbacher B. Tumor-specific lysis of human renal cell carcinomas by tumor-infiltrating lymphocytes: modulation of recognition through retroviral transduction of tumor cells with interleukin-2 complementary DNA and exogenous α-interferon treatment. Cancer Res. 53, 4020-4025 (1993).
72. Schoof DD, Terashima Y, Peoples GE et al. CD4+ T-cell clones isolated from human renal cell carcinoma possess the functional characteristics of Th2 helper cells. Cell Immunol. 150, 114-123 (1993).
73. Uhlman DL, Nguyen P, Manivel JC et al. Epidermal growth factor receptor and transforming growth factor-α expression in papillary and nonpapillary renal cell carcinoma: correlation with metastatic behavior and prognosis. Clin. Cancer Res. 1, 913-920 (1995).
74. Disis ML, Cheever MA. HER-2/neu protein: a target for antigen-specific immunotherapy of human cancer. Adv. Cancer Res. 71, 343-371 (1997).
75. Zhang XH, Takenaka I, Sato C, Sakamoto H p53 and HER-2 alterations in renal cell carcinoma. Urology 50, 636-642 (1997).
76. Seliger B, Rongcun Y, Atkins D et al. HER-2/neu is expressed in human renal cell carcinoma at heterogeneous levels independently of tumor grading and staging and can be recognized by HLA-A2. 1-restricted cytotoxic T-lymphocytes. Int. J. Cancer 87, 349-359 (2000).
77. Stumm G, Eberwein S, Rostock-Wolf S et al. Concomitant overexpression of the EGFR and erbB-2 genes in renal cell carcinoma (RCC) is correlated with dedifferentiation and metastasis. Int. J. Cancer 69, 17-22 (1996).
78. Disis ML, Smith JW, Murphy AE, Chen W, Cheever MA. In vitro generation of human cytolytic T-cells specific for peptides derived from the HER-2/neu proto-oncogene protein. Cancer Res. 54, 1071-1076 (1994).
79. Uemura H, Nakagawa Y, Yoshida K et al. MN/CA IX/G250 as a potential target for immunotherapy of renal cell carcinomas. Br. J. Cancer 81, 741-746 (1999).
80. Oosterwijk E, Bander NH, Divgi CR et al. Antibody localization in human renal cell carcinoma: a Phase I study of monoclonal antibody G250. J. Clin. Oncol. 11, 738-750 (1993).
81. Divgi CR, Bander NH, Scott AM et al. Phase I/II radioimmunotherapy trial with iodine-131-labeled monoclonal antibody G250 in metastatic renal cell carcinoma. Clin. Cancer Res. 4, 2729-2739 (1998).
82. Bui MH, Seligson D, Han KR et al. Carbonic anhydrase IX is an independent predictor of survival in advanced renal dear cell carcinoma: implications for prognosis and therapy. Clin. Cancer Res. 9, 802-811 (2003).
83. Atkins M, McDermott D, Mier J et al. Carbonic anhydrase IX (CAIX) expression predicts for renal cell cancer (RCC) patient response and survival to IL-2 therapy. Proc. Am. Soc. Clin. Oncol. 23, 383 (2004) (Abstract 4512).
84. Motzer RJ, Bacik J, Mariani T, Russo P, Mazumdar M, Reuter V. Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology. J. Clin. Oncol. 20, 2376-2381 (2002).
85. Vissers JL, De Vries IJ, Schreurs MW et al. The renal cell carcinoma-associated antigen G250 encodes a human leukocyte antigen (HLA)-A2. 1-restricted epitope recognized by cytotoxic T-lymphocytes. Cancer Res. 59, 5554-5559 (1999).
86. Vissers JL, De Vries IJ, Engelen LP et al. Renal cell carcinoma-associated antigen G250 encodes a naturally processed epitope presented by human leukocyte antigen-DR molecules to CD4(+) T-lymphocytes. Int. J. Cancer 100, 441-444 (2002).
87. Shimizu K, Uemura H, Yoshikawa M et al. Induction of antigen specific cellular immunity by vaccination with peptides from MN/CA IX in renal cell carcinoma. Oncol. Rep. 10, 1307-1311 (2003 ).
88. Tso CL, Zisman A, Pantuck A et al. Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor. Cancer Res. 61, 7925-7933 (2001).
89. Hernandez JM, Bui MH, Han KR et al. Novel kidney cancer immunotherapy based on the granulocyte-macrophage colony-stimulating factor and carbonic anhydrase IX fusion gene. Clin. Cancer Res. 9, 1906-1916 (2003).
90. Mukouyama H, Janzen NK, Hernandez JM et al. Generation of kidney cancer-specific antitumor immune responses using peripheral blood monocytes transduced with a recombinant adenovirus encoding carbonic anhydrase 9. Clin. Cancer Res. 10, 1421-1429 (2004).
91. Yu Z, Restifo NP. Cancer vaccines: progress reveals new complexities. J. Clin. Invest. 110, 289-294(2002).
92. Belldegrun A, Tso CL, Zisman A et al. interleukin-2 gene therapy for prostate cancer: Phase I clinical trial and basic biology. Hum. Gene Ther. 12, 883-892 (2001).
93. Simons JW, Jaffee EM, Weber CE et al. Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer. Cancer Res. 57, 1537-1546 (1997).
94. Antonia SJ, Seigne J, Diaz J et al. Phase I trial of a B7.1 (CD80) gene modified autologous tumor cell vaccine in combination with systemic interleukin-2 in patients with metastatic renal cell carcinoma. J. Urol. 167, 1995-2000 (2002).
95. Steinman RM. The dendritic cell system and its role in immunogenicity. Ann. Rev. Immunol. 9, 271-296 (1991).
96. Caux C, Vanbervliet B, Massacrier C et al. CD34+ hematopoietic progenitors from human cord blood differentiate along two independent dendritic cell pathways in response to GM-CSF+TNFα. J. Exp. Med. 184, 695-706 (1996).
97. Banchereau J, Palucka AK, Dhodapkar M et al. Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. Cancer Res. 61, 6451-6458 (2001).
98. Banchereau J, Pulendran B, Steinman R, Palucka K. Will the making of plasmacytoid dendritic cells in vitro help unravel their mysteries? J. Exp. Med. 192, F39-F44 (2000).
99. Shi Y, Rock KL. Cell death releases endogenous adjuvants that selectively enhance immune surveillance of particulate antigens. Eur. J. Immunol. 32, 155-162 (2002).
100. Assikis VJ, Daliani L, Pagliaro L et al. Phase II study of an autologous tumor derived heat shock protein-peptide complex vaccine (HSPPC-96) for patients with metastatic renal cell carcinoma (mRCC). Proc. Am. Soc. Clin. Oncol. 22, 386 (2003).
101. Dhodapkar W, Steinman RM, Krasovsky J, Munz C, BhardwaJ. N. Antigen-specific inhibition of effector T-cell function in humans after injection of immature dendritic cells. J. Exp. Med. 193, 233-238 (2001).
102. Thurner B, Haendle I, Roder C et al. Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T-cells and induces regression of some metastases in advanced stage IV melanoma. J. Exp. Med. 190, 1669-1678 (1999).
103. Toungouz M, Libin M, Bulte F et al. Transient expansion of peptide-specific lymphocytes producing IFN-γ after vaccination with dendritic cells pulsed with MAGE peptides in patients with mage-A1/A3-positive tumors. J. Leukoc. Biol. 69, 937-943 (2001).
104. Nestle FO, Alijagic S, Gilliet M et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nature Med. 4, 328-332 (1998).
105. Morse MA, Coleman RE, Akabani G, Niehaus N, Coleman D, Lyerly HK. Migration of human dendritic cells after injection in patients with metastatic malignancies. Cancer Res. 59, 56-58 (1999).
106. Fong L, Brockstedt D, Benike C, Wu L, Engleman EG. Dendritic cells injected via different routes induce immunity in cancer patients. J. Immunol. 166, 4254-4259 (2001).
107. Hsu FJ, Benike C, Fagnoni F et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nature Med. 2, 52-58 (1996).
108. Small EJ, Fratesi P, Reese DM et al. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J Clin. Oncol. 18, 3894-3903 (2000).
109. Holtl L, Rieser C, Papesh C et al. Cellular and humoral immune responses in patients with metastatic renal cell carcinoma after vaccination with antigen pulsed dendritic cells. J. Urol. 161, 777-782 (1999).
110. Gitlitz BJ, Belldegrun AS, Zisman A et al. A pilot trial of tumor lysate-loaded dendritic cells for the treatment of metastatic renal cell carcinoma. J. Immunother. 26, 412-419 (2003 ).
111. Gong J, Apostolopoulos V, Chen D et al. Selection and characterization of MUC1-specific CD8+ T-cells from MUC1 transgenic mice immunized with dendritic-carcinoma fusion cells. Immunology 101, 316-324 (2000).
112. Avigan DE, George DJ, Kantoff PW et al. Interim safety and efficacy results from a Phase I/II study of vaccination with electrofused allogeneic dendritic cells/autologous tumor-derived cells in patients with stage IV renal cell carcinoma. Proc. Am. Soc. Clin. Oncol. 23, 169 (2004) (Abstract 2526).
113. Su Z, Dannull J, Heiser A et al. Immunological and clinical responses in metastatic renal cancer patients vaccinated with tumor RNA-transfected dendritic cells. Cancer Res. 63, 2127-2133 (2003).
114. Chaput N, Schartz NE, Andre F, Zitvogel L. Exosomes for immunotherapy of cancer. Adv. Exp. Med. Biol. 532, 215-221 (2003).
115. McCune CS, O'Donnell RW, Marquis DM, Sahasrabudhe DM. Renal cell carcinoma treated by vaccines for active specific immunotherapy: correlation of survival with skin testing by autologous tumor cells. Cancer Immunol. Immunother. 32, 62-66 (1990).
116. Disis ML, Schiffman K, Gooley TA, McNeel DG, Rinn K, Knutson KL. Delayed-type hypersensitivity response is a predictor of peripheral blood T-cell immunity after HER-2/neu peptide immunization. Clin. Cancer Res. 6, 1347-1350 (2000).
117. Maino VC, Picker LJ. Identification of functional subsets by flow cytometry: intracellular detection of cytokine expression. Cytometry 34, 207-215 (1998).
118. Altman JD, Moss PA, Goulder PJ et al. Phenotypic analysis of antigen-specific T-lymphocytes. Science 274, 94-96 (1996).
119. Lee PP, Yee C, Savage PA et al. Characterization of circulating T-cells specific for tumor-associated antigens in melanoma patients. Nature Med. 5, 677-685 (1999).
120. Oosterwijk E, Ruiter DJ, Hoedemaeker PJ et al. Monoclonal antibody G 250 recognizes a determinant present in renal-cell carcinoma and absent from normal kidney. Int. J. Cancer 38, 489-494 (1986).
121. Bleumer I, Knuth A, Oosterwijk E et al. A Phase II trial of chimeric monoclonal antibody G250 for advanced renal cell carcinoma patients. Br. J. Cancer 90, 985-990 (2004).
122. 2a in metastatic renal cell carcinoma patients. Proc. Am. Soc. Clin. Oncol. 23, 407 (2004) (Abstract 4606).
123. Yang JC, Haworth L, Sherry RM et al. A randomized trial of bevacizumab, an antivascular endothelial growth factor antibody, for metastatic renal cancer. N. Engl. J. Med. 349, 427-434 (2003).
124. Rini BI, Halabi S, Taylor J, Small EJ, Schilsky RL. Cancer and Leukemia Group B 90206: a randomized Phase III trial of interferon-α or interferon-α plus antivascular endothelial growth factor antibody (bevacizumab) in metastatic renal cell carcinoma. Clin. Cancer Res. 10, 2584-2586 (2004).
125. Kim KJ, Li B, Winer J et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362, 841-844 (1993).
126. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nature Med. 9, 669-676 (2003).
127. Gabrilovich DI, Chen HL, Girgis KR et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nature Med. 2, 1096-1103 (1996).
128. Rowinsky EK, Schwartz GH, Gollob JA et al. Safety, pharmacokinetics, and activity of ABX-EGF, a fully human antiepidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer. J. Clin. Oncol. 22, 3003-3015 (2004).
129. Bex A, Horenblas S, Meinhardt W, Verra N, de Gast GC. The role of initial immunotherapy as selection for nephrectomy in patients with metastatic renal cell carcinoma and the primary tumor in situ. Eur. Urol. 42, 570-574 (2002).
130. Flanigan RC, Mickisch G, Sylvester R, Tangen C, Van Poppel H, Crawford ED. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J. Urol. 171, 1071-1076 (2004).
131. Messing EM, Manola J, Wilding G et al. Phase III study of interferon-α-NL, as adjuvant treatment for resectable renal cell carcinoma: an Eastern Co-operative Oncology Group/Intergroup trial. J. Clin. Oncol. 21, 1214-1222 (2003).
132. Clark JI, Atkins MB, Urba WJ et al. Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial. J. Clin. Oncol. 21, 3133-3140 (2003).
133. Galligioni E, Quaia M, Merlo A et al. Adjuvant immunotherapy treatment of renal carcinoma patients with autologous tumor cells and bacillus Calmette-Guerin: five-year results of a prospective randomized study. Cancer 77, 2560-2566 (1996).
134. Jocham D, Richter A, Hoffmann L et al. Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: Phase III, randomised controlled trial. Lancet 363, 594-599 (2004).
135. McDermott D, Flaherty L, Clark J et al. Randomized Phase III trial of high-dose interleukin-2 (HD IL2) versus subcutaneous (SC) IL2/interferon (IFN) in patients with metastatic renal cell carcinoma (RCC). Proc. Am. Soc. Clin. Oncol. 20 (2001) (Abstract 685).